HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 27742192.
- Also identified by DOI 10.1016/j.kint.2016.08.016.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The treatment of anemia with erythropoiesis-stimulating agents and iron supplementation has become the standard of care in patients with chronic kidney disease. Because of the risks associated with this approach, hypoxia inducible factor stabilizing prolyl hydroxylase inhibitors were developed as a potential treatment alternative. In recent phase 2 trials, these agents raised hemoglobin in a predictable and controlled manner and improved markers of iron metabolism. More experience is needed to establish long-term efficacy, tolerability, and safety, and to determine whether their use is associated with lower iron requirements.
Medical subject headings
- Anemia
- Hematinics
- Hypoxia-Inducible Factor-Proline Dioxygenases
- Renal Insufficiency, Chronic